We have evaluated many potential anti-cancer compounds in mice and rats. Our in-house expertise allows us to optimally design studies that provide critical preclinical efficacy data. CBI provides a variety of validated cell lines for the assessment of anti-tumor agents. We can help you advance your product by conducting the following evaluations:
- Numerous cell lines validated
- Subcutaneous, intravenous and orthotopic implantation, including infusion
- Immunocompromized and immunocompetent rodents, including knockout and transgenics and syngeneics
- Angiogenesis, gene therapy, nanoparticle and stem cell capabilities
- Maximization of test article effectiveness and minimum effective dosage
- Combination therapy
- Comparison of formulation and routes of administration
- Maximum tolerated dose and pharmacokinetics/pharmacodynamics including radiolabel
- ATCC and custom tumor cells lines
- Tumor growth data managed by LABCAT
- Supporting capabilities: clinical pathology, immunology, histopathology, immunohistochemistry
Validated Tumor Cell Lines at Comparative Biosciences, Inc.
| Breast | MDA MB-231, MCF-7, MDA-MB-435, 4T1 |
| Colon | Caco-2, HCT-116, COL 205, L5174T Carcinoma |
| Lung | A549, LS174T, Lewis Lung (syngeneic) |
| Prostate | LNCAP, PC-3, DU-145 |
| Melanoma | B16F0, B16F10 (syngeneic) |
| Ovarian | SK-OV-3, OVCAR 3 |
| CNS | U87-MG |
| Myeloid | Daudi |
| Pancreatic | PANC-I, PANC-II, ASPC1 |
Other ATCC lines and custom lines are available upon request.